Structure of the bone morphogenetic protein receptor ALK2 and implications for fibrodysplasia ossificans progressiva - Wikidata - wikimedia - TriplyDB

Structure of the bone morphogenetic protein receptor ALK2 and implications for fibrodysplasia ossificans progressiva

Structure of the bone morphogenetic protein receptor ALK2 and implications for fibrodysplasia ossificans progressiva

http://www.wikidata.org/entity/Q24623325

about

TGF-β/BMP signaling and other molecular events: regulation of osteoblastogenesis and bone formation Past strategies and future directions for identifying AMP-activated protein kinase (AMPK) modulators A new class of small molecule inhibitor of BMP signaling Structural basis of conformational transitions in the active site and 80′s loop in the FK506-binding protein FKBP12 Recurrent activating ACVR1 mutations in diffuse intrinsic pontine glioma Uncovering Molecular Bases Underlying Bone Morphogenetic Protein Receptor Inhibitor Selectivity Open access target validation is a more efficient way to accelerate drug discovery From mysteries to medicines: drug development for fibrodysplasia ossificans progressive Identification and characterization of regulatory elements in the promoter of ACVR1, the gene mutated in Fibrodysplasia Ossificans Progressiva.The genomic landscape of diffuse intrinsic pontine glioma and pediatric non-brainstem high-grade glioma The phenotype and genotype of fibrodysplasia ossificans progressiva in China: a report of 72 cases.ACVR1 mutations in DIPG: lessons learned from FOP.ACVR1 p.Q207E causes classic fibrodysplasia ossificans progressiva and is functionally distinct from the engineered constitutively active ACVR1 p.Q207D variant Structure-activity relationship of 3,5-diaryl-2-aminopyridine ALK2 inhibitors reveals unaltered binding affinity for fibrodysplasia ossificans progressiva causing mutants.Bone Morphogenetic Protein (BMP) signaling in development and human diseases Recurrent somatic mutations in ACVR1 in pediatric midline high-grade astrocytoma.BMP signaling mediated by constitutively active Activin type 1 receptor (ACVR1) results in ectopic bone formation localized to distal extremity joints.Alk2 regulates early chondrogenic fate in fibrodysplasia ossificans progressiva heterotopic endochondral ossification Statistical allosteric coupling to the active site indole ring flip equilibria in the FK506-binding domain.Neofunction of ACVR1 in fibrodysplasia ossificans progressiva.Unique genetic and epigenetic mechanisms driving paediatric diffuse high-grade glioma.Common mutations in ALK2/ACVR1, a multi-faceted receptor, have roles in distinct pediatric musculoskeletal and neural orphan disorders.Constitutively active ALK2 receptor mutants require type II receptor cooperation Granting immunity to FOP and catching heterotopic ossification in the Act.High-throughput screening for modulators of ACVR1 transcription: discovery of potential therapeutics for fibrodysplasia ossificans progressiva.FK506 activates BMPR2, rescues endothelial dysfunction, and reverses pulmonary hypertension.Everolimus induces Met inactivation by disrupting the FKBP12/Met complex Development of an ALK2-biased BMP type I receptor kinase inhibitor.Functional diversity and pharmacological profiles of the FKBPs and their complexes with small natural ligands.Conformational Dynamics in FKBP Domains: Relevance to Molecular Signaling and Drug Design Signaling Receptors for TGF-β Family Members.Structural Basis of Intracellular TGF-β Signaling: Receptors and Smads.Diffuse Intrinsic Pontine Glioma: Time for Cautious Optimism.Oncogenic Mechanisms of Histone H3 Mutations.TGF-β Family Signaling in Connective Tissue and Skeletal Diseases.Application of human induced pluripotent stem cells to model fibrodysplasia ossificans progressiva.Two tissue-resident progenitor lineages drive distinct phenotypes of heterotopic ossification.Cellular Hypoxia Promotes Heterotopic Ossification by Amplifying BMP Signaling.Polymodal allosteric regulation of Type 1 Serine/Threonine Kinase Receptors via a conserved electrostatic lock.Small molecules dorsomorphin and LDN-193189 inhibit myostatin/GDF8 signaling and promote functional myoblast differentiation.

P2860

Q26798172-499661E1-F820-40C0-BD03-45316037B07D Q26864679-7A792D4F-B0CA-4B96-B15A-121B951FC13C Q27678000-63D704D7-D515-4D11-B503-780300A4BA28 Q27681247-F22CC7C1-A36A-42CE-87EE-141BADBF48BB Q28237518-99EB4139-F104-4290-88A4-1843AE72D10B Q28546110-894C2852-884F-4E67-951F-E56E4FB04909 Q28547855-18460896-A154-4B52-B5FE-B47E01283163 Q33555767-3B675423-05FD-41D3-B139-6455E07A93CB Q33587847-2385D18F-AA24-4BED-AB65-88E2AD148812 Q33751426-C7EAA484-5ED8-4367-99A8-46158D2208DA Q34038254-07DCEA39-00EF-4172-9C0C-1CDC6EF846D6 Q34134675-683A8ADD-774F-40FB-9FAD-B51A25E39702 Q34211818-5C0A2834-30C5-4CBA-A9C8-3BF4858BC619 Q34313807-DA286988-8B87-45F1-801F-779E3EBAE2F0 Q34512444-9FD4963A-3E31-424D-87B6-78F263838458 Q34810691-9B98295C-A9C1-4BBA-B2A4-1C6433A503F6 Q35424255-65E4AC77-602C-4297-8D7C-D59EBD118779 Q35568492-31712303-DAFF-4AD9-8C2F-807830D83E82 Q35764663-D5F6B18E-BA2F-45D5-BBC7-0F91EBF3446E Q36394399-97067256-E09C-4777-A967-CD438FA1456B Q36561184-F2A7DA54-878A-439B-A903-560549FF63DE Q36578816-B71CCC7D-325A-4265-AD9F-47B352108E0F Q36978228-59271AAA-9D33-47E5-843D-F149E51E870B Q36981608-0F72F3F7-C916-4D0A-9D2F-F3723BB5F7B3 Q37036154-13228294-AEA2-4698-BC2E-4DF1210BA394 Q37052894-56756D15-4F93-4E76-A54B-E08553540ABB Q37457794-FB281A8A-6B43-4BEE-A36A-899FF2B5D21C Q37513815-BCFF8E12-422D-4F26-BDD6-9185468011E6 Q38065993-ABC580B6-915D-4069-B2FE-9FB6A255C28E Q38489442-E82287B4-4C15-4643-A725-89AD5D2CF470 Q38915720-AB4BDB6A-91AA-4A74-9D0F-644D88ACA9D8 Q38934096-0ED59094-0CFE-4B1E-85EE-B58599256C27 Q38963434-EDCD9F57-756C-4D40-8727-C39E014FC17A Q39013655-F4F356A2-2777-4429-A612-69A83B7A53AA Q39155183-71C037D5-5E44-4924-9D9D-91223353F284 Q39439904-22A0A702-9340-404D-8867-17F891E55BE1 Q40459563-6C2D8E25-875A-4948-86D5-2BEF8DD4F951 Q41009657-F03CCF22-35D3-43A9-AC0E-B8E8312C15B7 Q41577865-ED4855C2-6911-44ED-B61B-A396DF1B52D9 Q41761999-110A4208-A6ED-4D45-ABFD-4CB29A163FEC

P2860

Structure of the bone morphogenetic protein receptor ALK2 and implications for fibrodysplasia ossificans progressiva

http://www.wikidata.org/entity/Q24623325

description

2012 nî lūn-bûn

@nan

2012 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2012 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

name

Structure of the bone morphoge ...... splasia ossificans progressiva

@ast

Structure of the bone morphoge ...... splasia ossificans progressiva

@en

Structure of the bone morphoge ...... splasia ossificans progressiva

@nl

type

label

Structure of the bone morphoge ...... splasia ossificans progressiva

@ast

Structure of the bone morphoge ...... splasia ossificans progressiva

@en

Structure of the bone morphoge ...... splasia ossificans progressiva

@nl

altLabel

Structure of the Bone Morphoge ...... splasia Ossificans Progressiva

@en

prefLabel

Structure of the bone morphoge ...... splasia ossificans progressiva

@ast

Structure of the bone morphoge ...... splasia ossificans progressiva

@en

Structure of the bone morphoge ...... splasia ossificans progressiva

@nl

P1433

Q24623325-A5988DFB-01C0-479E-BB7F-5562EF9FA514

P1476

Q24623325-BAD15766-9F72-43F3-BAC9-9A0A93FE8C51

P2093

Q24623325-365246FA-5A0D-4AC7-972A-00153C771D25

Q24623325-50169C64-2D4B-42F9-9B9E-AF91B742C542

Q24623325-94E0DF5B-C9CC-4A91-8A37-CE33A84763DA

Q24623325-B49321C6-17EF-4013-A138-23FC9457F7DC

Q24623325-B61CF6AE-EFFB-416F-B337-7933C00F52EE

Q24623325-DC73A140-054E-4576-852F-6D0F74DD2E5D

P2860

Q24623325-06E079FB-658B-4C26-9597-E0F41304B0E4

Q24623325-09D1FEFD-7800-414A-9502-9DE1DCBCA86D

Q24623325-0DA99E25-E665-44D6-9F3B-296E93950449

Q24623325-16E92592-36F0-49B9-B445-F3E9380C06BB

Q24623325-17C96518-F7DD-4F85-B608-B99D4EEE1DBC

Q24623325-1B0E461F-FEAD-4B78-B80B-AFE4FC833470

Q24623325-1E01E946-A5B5-4DE0-9795-2CE17612D5CB

Q24623325-21878F2A-1BFC-4D58-A4FC-FB0C6999B469

Q24623325-24C77D53-9A28-4785-BE02-3457FE1E53FF

Q24623325-2EF195A9-A412-4530-8C92-73A58597A560

P304

Q24623325-6D83D24A-825E-4B6C-AE86-791846398F29

P31

Q24623325-B2680E38-C773-4B67-B2AD-7B89FA4BCE84

P3181

Q24623325-ADD7CD87-0E2A-4F8E-A6BC-9134E4F4C524

P356

Q24623325-6F499BB6-C61D-4F5C-A73E-6FD4D55B59F7

P407

Q24623325-E9EB899E-8E75-417B-B3B1-A10E64E4485D

P433

Q24623325-E9961864-3A7C-482B-B496-6D291EE3C4CA

P478

Q24623325-43E4C49C-5887-433B-B7EA-BF8E4EB66BC2

P50

Q24623325-24C0FA09-B467-4AD8-9853-9B9EBD8DFFCA

Q24623325-6AB8820D-9861-4B17-AC38-63095E7C4E0F

Q24623325-7A1E9D2D-C221-4952-9A8F-486B96E81124

Q24623325-E3A014C6-D797-474B-B41A-80DF61F510BF

Q24623325-FBAAAB93-8749-4545-9E0B-4D425519A374

P577

Q24623325-B9F21B5A-8074-4173-91FC-40CD9E58449A

P698

Q24623325-CB8C43D9-92AD-4A0E-B4C1-66D825CC3D95

P921

Q24623325-663FE819-5305-48E7-B5F4-AF11668A438F

Q24623325-6BE2E22A-25F4-4A0E-A2AC-A83245B0C7D4

Q24623325-9E7C7BBB-5D91-4D50-B9F2-B1EE49D724F9

Q24623325-A45BA4A0-830E-4712-9AAD-A14607BFD76E

P932

Q24623325-1C9A5BF1-61EB-4A59-BB8F-20E5E844E75F

P3181

P356

JBC.M112.365932

P1433

Journal of Biological Chemistry

P1476

Structure of the bone morphoge ...... splasia ossificans progressiva

@en

P2093

Alex N Bullock

http://www.w3.org/2001/XMLSchema#string

Caroline E Sanvitale

http://www.w3.org/2001/XMLSchema#string

Georgina Kerr

http://www.w3.org/2001/XMLSchema#string

Ivan Alfano

http://www.w3.org/2001/XMLSchema#string

James T Triffitt

http://www.w3.org/2001/XMLSchema#string

Jan H Boergermann

http://www.w3.org/2001/XMLSchema#string

P2860

Crystal structure of the cytoplasmic domain of the type I TGF beta receptor in complex with FKBP12

Structural basis of Smad1 activation by receptor kinase phosphorylation

Specific interaction of type I receptors of the TGF-beta family with the immunophilin FKBP-12

A recurrent mutation in the BMP type I receptor ACVR1 causes inherited and sporadic fibrodysplasia ossificans progressiva

BMP-2/4 and BMP-6/7 differentially utilize cell surface receptors to induce osteoblastic differentiation of human bone marrow-derived mesenchymal stem cells

BMP type I receptor inhibition reduces heterotopic [corrected] ossification

Transgenic mice overexpressing BMP4 develop a fibrodysplasia ossificans progressiva (FOP)-like phenotype

MolProbity: all-atom contacts and structure validation for proteins and nucleic acids

The TGF beta receptor activation process: an inhibitor- to substrate-binding switch

Crystal structure of a phosphorylated Smad2. Recognition of phosphoserine by the MH2 domain and insights on Smad function in TGF-beta signaling

P304

36990-8

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

2015233

http://www.w3.org/2001/XMLSchema#string

P356

10.1074/JBC.M112.365932

http://www.w3.org/2001/XMLSchema#string

P407

P433

44

http://www.w3.org/2001/XMLSchema#string

P478

287

http://www.w3.org/2001/XMLSchema#string

P50

Frank von Delft

Apirat Chaikuad

P577

2012-10-26T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

22977237

http://www.w3.org/2001/XMLSchema#string

P921

fibrodysplasia ossificans progressiva

protein structure

P932

3481300

http://www.w3.org/2001/XMLSchema#string